<DOC>
	<DOCNO>NCT01577238</DOCNO>
	<brief_summary>The primary objective study assess efficacy 1 % SPL7013 Gel compare placebo gel treatment bacterial vaginosis ( BV ) . After screen eligible participant randomize receive either 1 % SPL7013 Gel hydroxyethyl cellulose ( HEC ) placebo gel dose 5g administer vaginally bedtime 7 consecutive day . Participants assess BV ( Amsel criterion Nugent score ) screening/Baseline , last application ( End Treatment , EOT , Day 9-12 ) final study visit approximately 2-3 week last dose ( Test Cure , TOC , Day 21-30 ) .</brief_summary>
	<brief_title>A Phase 3 Study SPL7013 Gel ( VivaGel ) Treatment Bacterial Vaginosis</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Key eligibility criterion : Postmenarchal female , age 12 year Diagnosis BV Amsel criterion ( ie four follow signs/symptoms : presence white grey homogeneous discharge ; positive whiff test indicate amine ( fishy ) odor addition potassium hydroxide ; vaginal pH great 4.5 ; presence least 20 % clue cell total epithelial cell Nugent score least 4 Otherwise healthy , determined medical history , physical examination normal Pap smear document within 24 month screen</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>SPL7013</keyword>
	<keyword>VivaGel</keyword>
	<keyword>bacterial vaginosis</keyword>
	<keyword>BV</keyword>
</DOC>